Ipsen

News
Ipsen_Onivyde_pack_vial

ASCO-GI data sets up wider use of Ipsen's Onivyde

Ipsen and partner Servier hope to extend the uses of their pancreatic cancer therapy Onivyde into the first-line treatment setting, assisted by new phase 3 data reported at the ASCO-GI 2023

Patients
Co-creating a patient engagement impact framework

Co-creating a patient engagement impact framework

Recognising patients as key stakeholders and embedding the patient voice, in a meaningful way, into every stage of the medicine’s development process is gradually being recognised as a mean